This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
THE MAIN INDEX eked out last-minute gains on Tuesday after moving within a tight range as investors await the release of corporate earnings results in the coming weeks.
PSKXF BDOUY AYAAY UVRBY SECB BDOUF BDO MWP SYBJF URC PHSXY PSE MWIDE ALI UVRBF AYAAF
Many Philippine companies expand overseas to reach more consumers and increase revenues. Also, companies can utilize global markets to introduce unique products and services (https://www.bizjournals.com/).
SMCP1 UNITDSPR JBFCY PDMXY UVRBY RI SMGBY SMGBF 532432 SMC2B SMC2A JBFCF SMC SMC2D SMC2C SMC2F JFC DMPLF URC SMC2E UQNTY DMPL D03 UVRBF
TEN Philippine companies made it to the Nikkei Asian Review’s third annual list of Asia300 Power Performers Ranking, which ranks the most powerful and valuable listed companies in Asia.
JGSMY GTCAP GTCXY JGS CEBUY JBFCF MPCFF SPHXF SPHZF CEB JGSHF UVRBF AYAAF DMC MPCIY AYAAY JBFCY DMCIF UVRBY DMCP SMPH CEBUF MPI SPHXY JFC URC DMCHY ALI
The current port congestion in Thailand is expected to affect the arrival of sugar imports in the country as most of the shipments would be coming from the Southeast Asian nation.
URC UVRBY UVRBF
The benchmark Philippine Stock Exchange index (PSEi) closed lower yesterday as investors pocketed profits amid recent gains.
ICT JGSMY GTCAP GTCXY NOW JGS BDOUY ICTEF BDOUF PHSXY PSE SPHXF SPHZF JGSHF UVRBF AYAAF PSKXF AYAAY UVRBY SMPH BDO SPHXY URC DNOW ALI
After a two-year business downturn, regional industrial powerhouse Universal Robina Corp. expects to start turning the corner this year as the group seeks to stabilize the domestic coffee business amid cutthroat competition while improving overseas operations.
URC UVRBY UVRBF
JG SUMMIT Holdings, Inc. is hiking its capital spending for 2018 as it aims to grow its petrochemical, airline, property, food and beverage, and banking businesses amid higher oil prices in the world market and the further depreciation of the peso.
JGSMY JGS RBNTF CEBUY UVRBY RBLAY CEBUF RLC RRETY URC CEB JGSHF UVRBF RRHI
Gokongwei-led conglomerate JG Summit saw a 35.8-percent year-on-year drop in first quarter net profit to P4.82 billion on slower earnings from the petrochemical and food businesses alongside some foreign exchange losses.
MER CEBUF RLC URC CEBUY UVRBY RBLAY CEB UVRBF
The benchmark Philippine Stock Exchange index (PSEi) ended positive on Tuesday as investors, buoyed by positive sentiments overseas, defended the key 7,500 support.
PSKXF BDOUY AYAAY JBFCY UVRBY BDOUF BDO JBFCF JFC URC PHSXY PSE ALI UVRBF AYAAF
UNIVERSAL Robina Corp. (URC)’s attributable profit fell by 12% in the first quarter of 2018, as lower coffee volume, higher inflation, and the continued depreciation of the peso dragged down its operations in the Philippines.
JGSMY PSKXF JGS URC PHSXY PSE UVRBY JGSHF UVRBF
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET